Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
227.74
+3.21 (1.43%)
Oct 9, 2026, 9:37 AM EDT - Market open
Alnylam Pharmaceuticals Market Cap
Alnylam Pharmaceuticals has a market cap or net worth of $30.47 billion as of October 9, 2026. It is the 832nd most valuable company in the world and the 360th biggest in the United States. Its market cap has decreased by 48.41% in one year.
Market Cap
30.47B
Enterprise Value
30.15B
1-Year Change
-48.41%
Global Rank
Country Rank
#360 United States
Category
ChartMarket Cap Chart
Since June 1, 2004, Alnylam Pharmaceuticals's market cap has increased from $135.00M to $30.47B, an increase of 22,473.10%. That is a compound annual growth rate of 27.41%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 30.47B | -41.99% |
| Dec 31, 2025 | 52.54B | 73.09% |
| Dec 31, 2024 | 30.35B | 26.35% |
| Dec 29, 2023 | 24.02B | -17.84% |
| Dec 30, 2022 | 29.24B | 44.16% |
| Dec 31, 2021 | 20.28B | 34.32% |
| Dec 31, 2020 | 15.10B | 17.60% |
| Dec 31, 2019 | 12.84B | 74.32% |
| Dec 31, 2018 | 7.37B | -37.48% |
| Dec 29, 2017 | 11.78B | 266.69% |
| Dec 30, 2016 | 3.21B | -59.72% |
| Dec 31, 2015 | 7.98B | 6.90% |
| Dec 31, 2014 | 7.46B | 82.96% |
| Dec 31, 2013 | 4.08B | 326.36% |
| Dec 31, 2012 | 956.60M | 174.73% |
| Dec 30, 2011 | 348.20M | -16.32% |
| Dec 31, 2010 | 416.10M | -43.53% |
| Dec 31, 2009 | 736.80M | -28.05% |
| Dec 31, 2008 | 1.02B | -13.48% |
| Dec 31, 2007 | 1.18B | 71.64% |
| Dec 29, 2006 | 689.60M | 94.42% |
| Dec 30, 2005 | 354.70M | 136.47% |
| Dec 31, 2004 | 150.00M | 11.11% |
| Jun 1, 2004 | 135.00M | - |
View and export this data all the way back to 2004. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| argenx SE | 43.57B |
| Revolution Medicines | 40.32B |
| BeOne Medicines AG | 39.81B |
| Royalty Pharma | 32.32B |
| Roivant Sciences | 24.71B |
| BioNTech SE | 23.13B |
| Incyte | 22.85B |
| Insmed | 21.94B |